Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor

Michelle G. Baladi, Michael J. Forster, Michael B. Gatch, Richard B. Mailman, Danielle L. Hyman, Lawrence P. Carter, and Aaron Janowsky

Jazz Pharmaceuticals, Palo Alto, California (M.G.B., D.L.H., L.P.C.); Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas (M.J.F., M.B.G.); Departments of Pharmacology and Neurology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania (R.B.M.); University of Arkansas for Medical Sciences, Little Rock, Arkansas (L.P.C.); Research and Development Service, Veterans Affairs Portland Health Care System, Portland, Oregon (A.J.); and Departments of Psychiatry and Behavioral Neuroscience, and Methamphetamine Abuse Research Center, Oregon Health and Science University, Portland, Oregon (A.J.)

Received February 2, 2018; accepted June 4, 2018

ABSTRACT

Excessive sleepiness (ES) is associated with several sleep disorders, including narcolepsy and obstructive sleep apnea (OSA). A role for monoaminergic systems in treating these conditions is highlighted by the clinical use of US Food and Drug Administration–approved drugs that act on these systems, such as dextroamphetamine, methylphenidate, modafinil, and armodafinil. Solriamfetol (JZP-110) is a wake-promoting agent that is currently being evaluated to treat ES in patients with narcolepsy or OSA. Clinical and preclinical data suggest that solriamfetol may offer an important advancement in the treatment of ES in patients with narcolepsy or OSA.

Introduction

Excessive sleepiness (ES) is present in a wide range of sleep disorders, including narcolepsy and obstructive sleep apnea (OSA). In narcolepsy, ES is the clinical hallmark symptom, and is the symptom reported as having the most significant impact on patients’ lives (Morgenthaler et al., 2007; http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM377107.pdf). Moreover, the American Academy of Sleep Medicine recommends that a reduction in ES is one of the most critical aspects in the management of narcolepsy (Krahn et al., 2015). ES in OSA is a prominent symptom and may not resolve despite effective therapy with positive airway pressure (Veasey et al., 2006; Weaver and Chasens, 2007; Pépin et al., 2009; Gasa et al., 2013; Chapman et al., 2016). In patients with narcolepsy or OSA, ES can be a debilitating condition and often has a substantial impact on patients’ quality of life (Aldrich, 1989; George, 2007; Ozaki et al., 2008).

Monoaminergic systems [serotonin (5-HT), norepinephrine (NE), and dopamine (DA)] play a well recognized role in a variety of physiologic functions, including sleep-wake regulation (Jouvet, 1972; Steriade and McCarley, 1990; Jones, 2000; George, 2007; Ozaki et al., 2008). The clinical use of US Food and Drug Administration–approved drugs that act on these systems, such as dextroamphetamine, methylphenidate, modafinil, and armodafinil highlights the potential role of monoaminergic systems in treating sleep disorders, including narcolepsy and obstructive sleep apnea (OSA). A role for monoaminergic systems in treating these disorders is highlighted by the clinical use of US Food and Drug Administration–approved drugs that act on these systems, such as dextroamphetamine, methylphenidate, modafinil, and armodafinil. Solriamfetol (JZP-110) is a wake-promoting agent that is currently being evaluated to treat ES in patients with narcolepsy or OSA. Clinical and preclinical data suggest that solriamfetol may offer an important advancement in the treatment of ES in patients with narcolepsy or OSA.

American Academy of Sleep Medicine recommends that a reduction in ES is one of the most critical aspects in the management of narcolepsy (Krahn et al., 2015). ES in OSA is a prominent symptom and may not resolve despite effective therapy with positive airway pressure (Veasey et al., 2006; Weaver and Chasens, 2007; Pépin et al., 2009; Gasa et al., 2013; Chapman et al., 2016). In patients with narcolepsy or OSA, ES can be a debilitating condition and often has a substantial impact on patients’ quality of life (Aldrich, 1989; George, 2007; Ozaki et al., 2008).

Monoaminergic systems [serotonin (5-HT), norepinephrine (NE), and dopamine (DA)] play a well recognized role in a variety of physiologic functions, including sleep-wake regulation (Jouvet, 1972; Steriade and McCarley, 1990; Jones, 2000; Siegel, 2000; Wisor et al., 2001). Although the underlying pathophysiology of ES may differ among sleep disorders (review, see Slater and Steier (2012)), several lines of evidence associate ES, in part, with dysregulation of DA systems
studies were undertaken to characterize the mechanism of understanding differences in the therapeutic effects between (i.e., increase in sleep above baseline after pharmacologic behavior or pronounced locomotor activity; furthermore, this solriamfetol (150 mg/kg) were not accompanied by stereotyped (6 mg/kg), the effects of an equipotent wake-promoting dose of in mice (Hasan et al., 2009). In contrast to additional effective and tolerable therapies to improve wake- and Dauvilliers, 2015). These findings highlight the need for with limitations such as limited tolerability, suboptimal systems, such as dextroamphetamine https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020717s020s013s018lbl.pdf), and armodafinil https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021875s021lbl.pdf in patients with narcolepsy or OSA. However, the use of each of these medications is associated with limitations such as limited tolerability, suboptimal response, and abuse potential (Bastuji and Jouvet, 1988; Dauvilliers et al., 2002; Mignot and Nishino, 2005; Thorpy and Dauvilliers, 2015). These findings highlight the need for additional effective and tolerable therapies to improve wakefulness and to treat ES associated with narcolepsy or OSA. Solriamfetol, (R)-2-amino-3-phenylpropylcarbamate hydrochloride, formerly known as JZP-110 (Fig. 1), is a wake-promoting agent that is being evaluated as a potential treatment of ES in patients with narcolepsy or OSA. Collectively, clinical and preclinical data suggest that the wake-promoting effects of solriamfetol differ from currently approved medications such as modafinil and amphetamine. Although head-to-head comparisons of solriamfetol and other medications have not been conducted, the clinical effects of solriamfetol on wakefulness in narcolepsy may differ compared with the effects observed in previous studies of modafinil and armodafinil (Schwartz et al., 2003; Harsh et al., 2006; Ruoff et al., 2016, 2017). For instance, a post-hoc analysis of a phase 2b clinical trial of solriamfetol in patients with narcolepsy resulted in maximal differences between drug and placebo groups of 7.8 minutes on a 40-minute Maintenance of Wakefulness Test that was censored to 20-minutes to facilitate comparisons with data from other studies (Ruoff et al., 2017). In contrast, previous studies of modafinil and armodafinil showed maximal differences between drug and placebo groups ranging from 2.3 to 4.5 minutes using a 20-minute Maintenance of Wakefulness Test (US Modafinil in Narcolepsy Multicenter Study Group, 1998, 2000; Harsh et al., 2006). In a preclinical study, solriamfetol induced wakefulness in a manner that differed from d-amphetamine in mice (Hasan et al., 2009). In contrast to d-amphetamine (6 mg/kg), the effects of an equipotent wake-promoting dose of solriamfetol (150 mg/kg) were not accompanied by stereotyped behavior or pronounced locomotor activity; furthermore, this dose of solriamfetol did not produce rebound hypersomnia (i.e., increase in sleep above baseline after pharmacologic promotion of wakefulness; Hasan et al., 2009). To better understand differences in the therapeutic effects between solriamfetol and other wake-promoting drugs, the current studies were undertaken to characterize the mechanism of action of solriamfetol compared with stimulants and DA reuptake inhibitors.

Materials and Methods

In Vitro Transporter Assays. Binding and functional assays were carried out in transfected cells expressing cloned human monoamine transporters using methods described previously (Eshleman et al., 1999, 2013; Janowsky et al., 2001). In brief, human embryonic kidney (HEK293) cells expressing recombinant DNA for the human DAT (hDAT), 5-HT transporter (hSERT), or NE transporter (hNET) were grown to 80% confluence on 150-mm diameter tissue culture dishes. To prepare cell membranes, medium was removed and cells were washed with 10 ml of calcium- and magnesium-free phosphate-buffered saline. Lysis buffer (10 ml; 2 mM HEPES with 1 mM EDTA) was added. After 10 minutes, cells were scraped from plates and centrifuged at 30,000g for 20 minutes. The supernatant fluid was removed and the pellet was resuspended in 12–32 ml of 0.32 M sucrose. Each assay tube contained 50 μl of membrane preparation, 25 μl of test compound (concentration range 21.6 nM to 100 μM for hDAT and hSERT and 21.6 nM to 10 μM for hNET), compound used to define nonspecific binding or buffer, 25 μl of [125I]RTI-55 (40–80 PM final concentration; specific activity 2200 Ci/mmol), and additional buffer sufficient to bring up the final volume to 250 μl. Membranes were preincubated with test compounds for 10 minutes prior to the addition of the [125I]RTI-55 followed by incubation at 25°C for 90 minutes. Binding was terminated by filtration over grade C glass-microfiber (GF/C) filters using a 96-well cell harvester, filters were washed with ice-cold saline, and scintillation fluid was added. Specific binding was defined as the difference in binding observed in the presence and absence of 5 μM mazindol (hDAT and hNET) or 5 μM imipramine (hSERT). Two or three independent experiments were conducted with duplicate (binding) or triplicate (reuptake and release) determinations. GraphPad Prism (GraphPad Software, Inc., La Jolla, CA) was used to convert values for inhibitor concentration resulting in half inhibition (IC50) to Ki values using the bimolecular Cheng-Prusoff relationship (Cheng and Prusoff, 1973). Additionally, reuptake and release of [3H]DA, [3H]NE, and [3H]5-HT in HEK293 cells were performed as described above (Eshleman et al., 1999, 2013; Janowsky et al., 2001). For reuptake, the concentration of solriamfetol tested was 31.6 nM to 100 μM for hSERT and hNET and 31.6 nM to 10 μM for hDAT. For release, the concentration of solriamfetol tested was 1 nM to 10 μM for hSERT and hNET and 1 nM to 100 μM for hDAT.

Binding assays for monoamine transporters were also carried out in rat brain membranes using methods described previously (Walker and Mailman, 1996). In brief, tissue was homogenized in 50 mM Tris-HCl, pH 7.4 buffer, centrifuged (25,500g, 4°C, 10 minutes) and diluted in assay buffer, prior to protein content measurement. For [3H]WIN 55428 binding, 250 μg of homogenized rat striatum was incubated (buffer: 10 mM Na2HPO4, 320 mM sucrose, pH 7.45) with test compound for 15 minutes at 21°C in the presence and absence of mazindol (1 μM). Reuptake and release assays for DAT, NET, and
SERT were carried out in rat brain synaptosomes using published methods. For reuptake inhibition assays, striatum was used for DA reuptake assays, and hypothalamus for NE reuptake studies using methods described previously (Heffner and Seiden, 1980; Mottola et al., 1992). For release assays, rat striatum was used for DA release and rat frontal cortex for 5-HT and NE release using methods described previously (Mottola et al., 1992). Each experimental point was conducted with triplicate determinations.

**In Vitro Receptor Assays.** Receptor binding studies were conducted with several reference ligands (chosen for their affinity and selectivity for the particular receptor in each assay) in membrane extracts from tissue expressing a receptor of interest, or from cell lines expressing the transfected receptor. Control wells (blank) contained cold reference compounds in sufficient concentration to block the binding of the radioligand. Generally, frozen membranes were thawed and briefly homogenized prior to dilution to an appropriate protein concentration optimized for specific and nonspecific binding. Radioligand was prepared by dilution in assay buffer to a suitable concentration, then incubated with a 10% dimethyl sulfoxide control (final concentration 1% dimethyl sulfoxide), solrifamfetol (10⁻³ to 10⁻⁵ M), and in the case of adrenergic receptors hα2A, hα2B, and hα2C, up to 10⁻⁴ M), or competing cold compound, plus membrane preparations from cells or tissue expressing the receptor of interest. Binding to D₁-like and D₂-like receptors used methods as described previously (Lewis et al., 1998; Mottola et al., 2002). For measurement of 5-HT₁A functional activity, agonist activation was determined by comparison with 5-HT (10 nM) as a control (100%). Antagonism was determined by inhibition of GTPγS binding by compound in the presence of a submaximal activation concentration of 5-HT (0.1 μM). Membrane-bound activity was collected by filtration either through a Packard Filtermate 196 Harvester (Packard Instrument Company, Inc., Meriden, CT) onto UniFilter plates (cell membranes; GE Healthcare Life Sciences, Pittsburgh, PA) or by Brandel tissue harvester (Brandel, Inc., Gaithersburg, MD) on grade GF/B filters, and by subsequent washing with ice-cold buffer (3 × 4 ml) or by scintillation proximity assay–based detection methods. Membranes were allowed to dry before adding scintillation fluid and counting in a TopCount scintillation counter (PerkinElmer, Inc., Waltham, MA). Percentage specific- and competition-binding curves were calculated using S-Plus software (Statistical Sciences, Seattle, WA).

Binding to the cloned human histamine H₃ receptor was carried out in transfected SK-N-MC cells, using methods described previously (Lov Bênberg et al., 2000). Briefly, cell pellets from SK-N-MC cells expressing the human H₃ receptor were homogenized in 50 mM Tris-HCl/5 mM EDTA and recentrifuged at 30,000 g for 30 minutes. Pellets were then homogenized in 50 mM Tris-5 mM EDTA (pH 7.4). Membranes were incubated with 0.8 nM [³H]-α-methylhistamine plus/minus test compounds for 45 minutes at 25°C and harvested by rapid filtration over GF/C filters (pretreated with 0.3% polyethylene) followed by four washes with buffer. Nonspecific binding was defined in the presence of 100 μM histamine.

Orexin receptor-2 functional assays were performed as described previously (McAtee et al., 2004). Briefly, PFSK-1 cells (human neuroectodermal cell line expressing human orexin receptor-2) were stimulated with agonists of orexin receptor-2 to increase intracellular Ca²⁺, which was measured with the FLIPR instrument (Molecular Devices, LLC, Sunnyvale, CA). On day 1, the PFSK-1 cells were plated onto 96-well Packard ViewPlates in RPMI 1640 (Packard Instrument Company, Inc.) supplemented with 10% fetal bovine serum and penicillin/streptomycin, then allowed to grow overnight at 37°C. On day 2, the medium was removed and replaced with Dulbecco’s modified Eagle’s medium nutrient mixture F-12 (Thermo Fisher Scientific, Inc., Waltham, MA) containing Flu-o-3 AM (a Ca²⁺-sensing fluorescent dye) and F-127 detergent. After allowing the cells to load the fluorescent dye for 1 hour at room temperature, the FLIPR instrument was used to apply various doses of solrifamfetol and to follow any changes in intracellular Ca²⁺ for 2 minutes. After an additional 10-minute incubation at room temperature, the same cell plate was assayed for the Ca²⁺ response to 100 nM orexin-A in the same manner.

Solrifamfetol was also tested at a concentration of 1 μM in a battery of additional assays for inhibition of radioligand binding by Eurofins Cerep SA (Celle L’Evescault, France) that included human A₁, A₂A, and A₃ adenosine receptors; α₁- and α₂-adrenergic receptors; human β₁-adrenergic receptor; human AT₁ angiotensin receptor; benzodiazepine receptor; human bradykinin receptor; human CCK₁ cholecystokinin receptor; human DA receptors D₁ and D₂ human endothelin receptor type A; GABAB receptor; human galanin receptor; human CXC chemokine receptors; human C-C chemokine receptor type 1; H₁ and H₂ histamine receptors, human M₄ muscarinic receptor; MT1 melatonin receptor; human M₁, M₂, and M₃ muscarinic acetylcholine receptors; human NK₁ and NK₂ neurokinin receptors; human Y₁ and Y₂ neuropeptide receptors; human NTS₂ neurotensin receptor; human μ, δ, and κ-opioid receptors and opioid-like receptor; human 5-HT₁A, 5-HT₁B, 5-HT₁D, 5-HT₂A, 5-HT₅, and 5-HT₇ serotonin receptors; somatostatin receptor PerkinElmer, Inc. (Waltham, MA) human vasoactive intestinal peptide receptor; human vasopressin receptor; and Ca²⁺, K⁺, SK⁺, Na⁺, and Cl⁻ channels. Solrifamfetol was also tested at a concentration of either 1 or 10 μM in a panel of more than 100 kinases (KinaseProfiler screening service; Upstate Biotechnology, Inc., Charlottesville, VA).

**Ex Vivo Autoradiography.** α₂-Adrenergic receptor density was assessed via [³H]RS79948-197 and [³H]rauwolscine binding to brain areas showing high receptor density (septum and caudate putamen) using methods reported previously (Schotte et al., 1996). Briefly, rats were treated by subcutaneous administration of vehicle or solrifamfetol at a dose of 40 mg/kg (three animals per treatment). The animals were decapitated 1 hour after administration. Brains were immediately removed from the skull and rapidly frozen in 2-methylbutanone on dry ice and stored at ~40°C. Twenty micrometer-thick sections were cut using a Leica CM3050 cryostat-microtome (Leica Microsystems Belgium BVBA, Diegem, Belgium), and thaw-mounted on microscope slides (Superfrost Plus Slides; Labonord, Templemars, France). The sections were then kept at ~20°C until use. After thawing, sections were dried under a stream of cold air. The sections were not washed prior to incubation to avoid dissociation of the drug receptor complex. Brain sections were incubated for 10 minutes in Tris-HCl buffer (50 mM, pH 7.4) containing 3 nM [³H]RS79948-197 or in Na-K-phosphate buffer (50 mM, pH 7.7) containing 0.8 nM [³H]rauwolscine. Nonspecific binding was determined by slides containing 10 μM rauwolscine (for [³H]RS79948-197 binding) or by slides containing 10 μM phenolamine (for [³H]rauwolscine binding). After the incubation, the excess of radioactivity was washed off in consecutive baths of ice-cold buffer, followed by a quick rinse in ice-cold water. The sections were then dried under a stream of cold air. Brain slices incubated with tritiated ligands were loaded in the β-imager (BioSpace Lab, Paris, France) for 1 hour. Acquired images were quantified using the β VISION program (BioSpace Lab). Specific binding was given as the difference between total binding and nonspecific binding measured in adjacent sections.

**Animals.** All animals were maintained under controlled environmental conditions on a 12-hour light-dark cycle with standard laboratory chow and water available ad libitum (with the exception of drug discrimination experiments described below). For in vitro binding and functional assays using rat brain synaptosomes, male Sprague-Dawley rats weighing 200–400 g were purchased from Charles River Laboratories (Raleigh, NC). For ex vivo autoradiography, male Wistar rats weighing 200 g were purchased from Charles River Laboratories (Sulzfeld, Germany). For microdialysis experiments, male Sprague-Dawley rats (Harlan Laboratories, Inc., Horst, The Netherlands) weighing 300–400 g were individually housed in full-view Plexiglas containers (25 × 33 × 18 cm) located in a sound-attenuated room. The animals were allowed to acclimate for at least 7 days prior to surgery. For locomotor experiments, male Swiss-Webster mice were obtained from Harlan Laboratories, Inc. (Indianapolis, IN) and were group housed. For drug discrimination experiments, male Sprague-Dawley...
rats were obtained from Harlan Laboratories, Inc. and were housed individually. Body weights were maintained at 320–350 g by limiting food to 15 g/day; water was continuously available in the home cage. The Institutional Animal Care and Use Committees approved all animal procedures.

**In Vivo Microdialysis.** Thirty-six rats were surgically implanted with two guide cannulae (CMA Microdialysis AB, Kista, Sweden): one into the striatum and the other into the prefrontal cortex using methods described previously (Gregory et al., 2019). Briefly, rats were anesthetized with inhaled isoflurane and a 30% O₂/70% N₂O mixture and were mounted in a stereotactic apparatus while situated on an isothermic heating blanket that maintained core body temperature at 37°C. Two small holes were drilled through the skull at the following coordinates taken from Paxinos and Watson (1998): incisor bar set at −3.5 mm, +2.75 mm anterior to and 0.75 mm lateral to bregma for the prefrontal cortex, and +0.5 mm anterior to and 2.5 mm lateral to bregma for the striatum. Five more holes were made in the skull, two adjacent to the cannulae and three in the contralateral parietal plate. Five self-tapping gold-plated anchor screws were screwed in these holes and two guide cannulae (CMA/12) with inserted dummy probes were lowered into the brain. The cannulae were lowered through the surface of the brain (tips ventral at 0.75 mm for the prefrontal cortex and at 3.25 mm for the striatum) and glued to the screws using 3M dental cement. Screws and cannulae were then embedded within dental cement to smooth the headset. After surgery, the animals were housed individually and allowed to recover for at least 10 days prior to experimentation. After the experiment, all animals were sacrificed for histologic verification of probe placement: An animal was excluded from the analysis if other brain structures were affected or if lesions were found with more than 0.5 mm divergence from the target coordinates in two or more planes.

One day prior to testing, rats were transferred to the experimental room and inserted with microdialysis probes. The next day, dialysates were collected in three consecutive 50-minute baseline samples, followed by eight consecutive 50-minute postadministration samples of vehicle (saline, 0.9% NaCl) or solriamfetol (10 and 30 mg/kg, administered s.c.) in separate groups of rats (n = 12/condition). Microdialysates were analyzed by high-performance liquid chromatography with a Waters 2465 electrochemical detector and 0.7-mm capillary cell with glassy carbon electrode. Data are presented as the average percent change in neurotransmitter concentration of a certain postadministration sample compared with the individual animal’s average baseline value (i.e., the mean for that animal over the three baseline samples). A total of three baseline samples and eight consecutive postadministration samples were analyzed. The average value and corresponding S.E. were then calculated for each 50-minute sample.

**Drug Discrimination.** Six rats were trained to discriminate cocaine (10 mg/kg) from saline using a two-lever choice task. Food was available as a reinforcer under a fixed-ratio-10 schedule when responding occurred on the injection-appropriate lever. All tests occurred in standard, commercially available chambers (Coulbourn Instruments, Holliston, MA) and were conducted during periods of identical training sessions (i.e., between either two saline or two cocaine training sessions). Tests occurred only if, in the two preceding training sessions, rats met the criteria of at least 85% of responses on the injection-appropriate (i.e., the “correct”) lever for both the first reinforcer (first fixed ratio) and the total session. Test sessions lasted for 20 minutes, or until 20 reinforcers had been obtained. Injections (1 mg/kg i.p.) of solriamfetol or its vehicle (0.9% saline) occurred 60 minutes prior to the start of the test session. Drug discrimination data are expressed as the average percentage of the total responses occurring on the cocaine-appropriate lever during the entire response period.

**Locomotor Activity.** Separate groups of mice (n = 8/condition) were injected with vehicle (0.9% saline), cocaine (5, 10, 20, or 40 mg/kg; i.p.), or solriamfetol (3, 10, 30, or 100 mg/kg; i.p.) immediately prior to locomotor activity testing. The locomotor study was conducted using 40 Digiscan locomotor activity testing chambers (Omnitech Electronics, Inc., Columbus, OH) measuring 40.5 × 40.5 × 30.5 cm, and the mice were housed in sets of two within sound-attenuating chambers. A panel of 16 infrared beams and corresponding photodetectors were located in the horizontal direction along the sides of each activity chamber. A 7.5-W incandescent light above each chamber provided dim illumination. Fans provided an 80-dB ambient noise level within the chamber. In all studies, horizontal activity (interception of photocell beams) was measured for 8 hours within 10-minute periods, beginning at 8:00 AM (2 hours after lights on). Testing was conducted with one mouse per activity chamber. For presentation of locomotor data, the average effect was taken for each animal during the first 30 minutes of the recording period. The statistical significance of differences between the mean of vehicle and the mean of each dose of drug was assessed by a Student t test.

**Chemicals, Reagents, and Drug Treatments.** Solriamfetol was provided by SK Life Science, Inc. (Fair Lawn, NJ) or Janssen Pharmaceuticals (Raritan, NJ). For in vitro binding and functional assays, radioligands were purchased commercially from NEN Life Sciences inc., (Boston, MA), Amersham Biosciences (Little Chalfont, United Kingdom), or PerkinElmer, Inc. (Waltham, MA), including: [3H]mazindol, [3H]clonidine, [3H]GBR-12909, [3H][RTI-55, [3H]DA, [3H]NE, and [3H]5-HT. The following drugs were received as gifts: fluoxetine (Lilly Research Laboratories, Indianapolis, IN) and GBR-12909 (Novo Industries, Bagsvaerd, Denmark). HEPE buffer was purchased from Research Organics, Inc. (Cleveland, OH). Other drugs and reagents were of highest available purity and were purchased from commercial sources.

**Results**

**In Vitro Transporter and Receptor Assays.** The first set of binding studies examined the interaction of solriamfetol with monoamine transporters (DAT, NET, and SERT) in transfected cells and rat brain synaptosomes. As indicated in Table 1, solriamfetol binds to DAT and NET. The affinity of solriamfetol for these transporters was lower than that of cocaine in transfected cells. For example, the binding affinity of solriamfetol for DAT was 60-fold lower than the binding affinity of cocaine for DAT (K<sub>i</sub> values = 14,200 and 236 nM, respectively) and the binding affinity of solriamfetol for NET was 7-fold lower than the binding affinity of cocaine for NET (K<sub>i</sub> values = 3700 and 505 nM, respectively; Table 1). Further, solriamfetol had negligible binding affinity at the SERT compared with cocaine (K<sub>i</sub> values = 81,500 and 361 nM, respectively). Studies conducted in rat striatal synaptosomes replicated and extended the finding that solriamfetol interacts with DAT (Table 1). In these studies involving rat brain tissue, solriamfetol had a lower affinity for DAT compared with cocaine. For example, cocaine displaced [3H]WIN 35428 binding with an IC<sub>50</sub> of 160 nM, whereas solriamfetol displaced [3H]WIN 35428 binding with an IC<sub>50</sub> of 2600 nM (Table 1).

Monoamine reuptake inhibition and release assays were conducted to investigate how solriamfetol functionally interacts with monoamine transporters. In transfected cells, solriamfetol blocked the reuptake of [3H]DA and [3H]NE (IC<sub>50</sub> = 2900 and 4400 nM, respectively; Table 2). However, solriamfetol was a less potent inhibitor compared with cocaine (IC<sub>50</sub> = 385 and 194 nM at DAT and NET, respectively; Table 2). Further, solriamfetol did not have significant functional activity at blocking the reuptake of [3H]5-HT, compared with cocaine. Additional studies in rat brain...
Results from the receptor binding assays in heterologously transfected cells showed that solriamfetol (10 or 100 μM) did not have significant affinity for any receptors except 5-HT1A and α2-adrenergic receptors (Table 3). Subsequent functional assays demonstrated that solriamfetol did not have any functional activity at 5-HT1A receptors (neither stimulation nor inhibition) at the maximum concentration (10 μM) tested. Further, a subsequent study evaluated α2-adrenergic binding sites by quantitative autoradiography using two different α2-adrenergic radioligands ([3H]RS79948-197 or [3H]rauwolscine). There were no differences in either [3H]RS79948-197 or [3H]rauwolscine binding density between solriamfetol- and vehicle-treated rats. Of note, solriamfetol had no significant interactions with histamine H1 or H3 receptors (i.e., Kᵢ > 10 μM), did not activate orexin-2 receptors, and did not inhibit the stimulatory effects of orexin-A. No additional significant interactions were observed in evaluations performed at Eurofins Cerep SA (see Materials and Methods for the assays included). In the kinase screen, no broad enzyme inhibition or activation was observed (including monoamine oxidase A and B), suggesting that solriamfetol is not a nonspecific kinase inhibitor (see Materials and Methods for the assays included).

Drug Discrimination. To evaluate the mechanism of action of solriamfetol in vivo, solriamfetol was tested for its ability to substitute for cocaine in rats trained to discriminate cocaine from saline. In six rats trained to discriminate 10 mg/kg cocaine from saline, solriamfetol occasioned responding on the cocaine-appropriate lever in a dose-dependent manner, with a dose of 100 mg/kg occasioning more than 80% cocaine-appropriate responding [solriamfetol ED₅₀: 37.6 mg/kg (95% CI: 6.63–213.41 mg/kg); Fig. 3A]. Solriamfetol also dose dependently decreased the rate of responding such that a 100-mg/kg dose of solriamfetol resulted in a significant decrease in response rate to approximately 40% of control and one of five rats failed to complete the first fixed-ratio (Fig. 3B).

### Table 1

| Binding Affinity (Kᵢ or IC₅₀) | Cell/Tissue Type | HEK293 Cells | Rat Brain Synaptosomes (Striatum) | Rat Brain Synaptosomes (Striatum) |
|-------------------------------|-----------------|--------------|-------------------------------|-------------------------------|
|                               |                 | Cocaine      | Solriamfetol                  | Cocaine      | Solriamfetol                  |
| DAT                           | nM              | 236 ± 58     | 14,200 ± 3500                 | 160⁹         | 2600⁹                       |
| NET                           | nM              | 505 ± 67     | 3700 ± 1000                   | ND            | ND                          |
| SERT                          | nM              | 361 ± 55     | 81,500 ± 2900                 | ND            | ND                          |
| DAT                           | nM              | 30⁷           | 4100⁷                        | ND            | ND                          |
| NET                           | nM              | ND           | ND                            | ND            | ND                          |
| SERT                          | nM              | ND           | ND                            | ND            | ND                          |

ND, no data.

Radioligand used was [3H]RS79948-197 or [3H]rauwolscine. There were no differences in either [3H]RS79948-197 or [3H]rauwolscine binding density between solriamfetol- and vehicle-treated rats. Of note, solriamfetol had no significant interactions with histamine H1 or H3 receptors (i.e., Kᵢ > 10 μM), did not activate orexin-2 receptors, and did not inhibit the stimulatory effects of orexin-A. No additional significant interactions were observed in evaluations performed at Eurofins Cerep SA (see Materials and Methods for the assays included). In the kinase screen, no broad enzyme inhibition or activation was observed (including monoamine oxidase A and B), suggesting that solriamfetol is not a nonspecific kinase inhibitor (see Materials and Methods for the assays included).

### Table 2

| Reuptake Inhibition (IC₅₀) | Cell/Tissue Type | HEK293 Cells | Rat Brain Synaptosomes⁹ | GBR-12909 Bupropion | Desipramine | Solriamfetol |
|----------------------------|-----------------|--------------|-------------------------|---------------------|-------------|--------------|
|       |                 | Cocaine      | Solriamfetol            | GBR-12909 Bupropion | Desipramine | Solriamfetol |
| [3H]DA | nM              | 385 ± 54     | 2900 ± 920              | 8                   | 1700        | ND           |
| [3H]NE | nM              | 194 ± 29     | 4400 ± 1100             | ND                  | ND          | 4.2          |
| [3H]5-HT | nM            | 355 ± 39     | >100,000                | ND                  | ND          | 6500         |
| Release (EC₅₀)⁶ | HEK293 Cells | Meth         | PCA                     | Solriamfetol        |             |
|                                   | nM              | nM              | nM                     |                     |
| [3H]DA | 721 ± 96       | ND                  | NA                     |                     |
| [3H]NE | 103 ± 35       | ND                  | NA                     |                     |
| [3H]5-HT | 22,800 ± 700  | 430 ± 120             | NA                     |                     |

GRB-12909, (1-(2-bis(4-fluorophenyl)-methoxy)-ethyl)-4-(3-phenyl-propyl)piperazine; Meth, methamphetamine; NA, a sigmoidal curve could not be fit to the data; ND, no data; PCA, p-chloroamphetamine.

⁹Rat brain striatum for DAT and hypothalamus for NET.

⁶Release (EC₅₀) testing performed only in HEK293 cells. For experiments using cells, numbers represent the means ± S.E. from at least three independent experiments, each conducted with triplicate determinations.
Locomotor Activity. To examine whether solriamfetol shared other behavioral effects with cocaine, the locomotor effects of solriamfetol were compared with cocaine. As shown in Fig. 4A, cocaine dose dependently increased locomotor activity resulting in an inverted U-shaped curve. The maximum average (± S.E.) effect was 6817 (± 545) ambulation counts at 20 mg/kg cocaine compared with 3599 (± 178) ambulation counts with vehicle (eight mice/treatment; P < 0.05). In contrast to the dose-response curve for cocaine, Fig. 4B shows that the effects of solriamfetol on locomotor activity were minimal with decreases observed at the largest dose (100 mg/kg; P < 0.05). The maximum average effect was 3802 (± 178) ambulation counts at 30 mg/kg solriamfetol compared with 2997 (± 166) ambulation counts with vehicle (P < 0.05).

In Vivo Microdialysis. For microdialysis experiments, a maximal dose of 30 mg/kg solriamfetol was selected based on the observation that doses >30 mg/kg solriamfetol decreased rate of responding [albeit a different route of administration (s.c.) was used for the drug discrimination experiment]. At a dose of 30 mg/kg, but not 10 mg/kg, solriamfetol increased...
Together, these data suggest that the behavioral effects of solriamfetol (30 mg/kg) produced a peak increase of approximately 350% in DA levels approximately 125 minutes after injection, compared with baseline. Solriamfetol-induced increases in DA levels were observed through the remainder of the sampling period (Fig. 5A). Specifically, 75 minutes after injection, solriamfetol (30 mg/kg) produced a peak increase of approximately 350% in prefrontal cortical NE extracellular levels compared with baseline (Fig. 5B). Solriamfetol-induced increase in NE levels returned to baseline around 275 minutes after injection (i.e., sampling period at 450 minutes; Fig. 5B). No effects of solriamfetol (at doses of 10 and 30 mg/kg) on 5-HT levels could be detected in either the striatum or frontal cortex compared with baseline levels (Jazz Pharmaceuticals, data on file).

**Discussion**

Collectively, data from the current studies demonstrate that the mechanism of action of solriamfetol includes low potency DA and NE reuptake inhibition via DAT and NET, respectively, without significant activity at any other target studied to date. In rats, a dose of solriamfetol (35 mg/kg; PO) produces a plasma C\text{max} of 23.1 μM (Jazz Pharmaceuticals, data on file); brain concentrations are expected to be similar to the plasma concentrations based on the high solubility, high permeability, and low plasma protein binding of solriamfetol. The plasma concentration of 23.1 μM is higher than both the binding affinity (K_i) for DAT and NET and the IC\text{50} for DA or NE reuptake inhibition (see Tables 1 and 2), suggesting that the in vivo effects of solriamfetol in rodents are mediated through mechanisms involving DAT and NET. Consistent with this notion, microdialysis experiments showed that a dose of 30 mg/kg (s.c.) solriamfetol increased DA and NE levels in the striatum and prefrontal cortex, respectively. In addition, the finding that solriamfetol generalized to cocaine in rats trained to discriminate cocaine from saline supports the conclusion that solriamfetol has activity at DAT and NET in vivo, as several studies support a role for DA and NE reuptake in the discriminative stimulus effects of cocaine (Kleven et al., 1990; Baker et al., 1993; Spealman, 1995). Together, these data suggest that the behavioral effects (e.g., wake-promoting effects) of solriamfetol are attributable to its activity at DAT and NET, rather than other neurotransmitter receptors involved in sleep-wake regulation, such as histamine or orexin receptors (Lin et al., 2011; Dauvilliers et al., 2013; De la Herrán-Arita and García-García, 2013).

Results from the binding and reuptake studies indicate that solriamfetol has negligible binding affinity and functional activity at SERT (Tables 1 and 2). In addition, solriamfetol (at doses of 10 and 30 mg/kg) did not increase 5-HT extracellular levels in brain as shown in microdialysis experiments. Data from other studies have also demonstrated that solriamfetol does not have a serotoninergic mechanism of action in vivo on the basis of findings that solriamfetol did not resemble the effects of fluoxetine, a selective serotonin reuptake inhibitor. For instance, 5-hydroxytryptophan (5-HTP) induces head twitches in rodents (Corne et al., 1963), which is presumed to be mediated by the 5-HT\text{2A} receptor subtype (Halberstadt et al., 2011; Canal and Morgan, 2012). In contrast to the effects of fluoxetine, which shifted the 5-HTP dose-response curve for head twitches to the left in mice, solriamfetol (30 and 60 mg/kg) did not potentiate 5-HTP-induced head twitches (Jazz Pharmaceuticals, data on file). Together, the in vitro and in vivo data indicate that solriamfetol does not have activity at SERT or 5-HT receptors.

Several lines of evidence suggest that the mechanism of action of solriamfetol differs from currently available stimulants (e.g., amphetamines) and wake-promoting agents (e.g., modafinil) with regard to activity at monoamine transporters. For instance, and in contrast to the well-known monoamine-releasing effects of amphetamine (see Rothman et al. (2001)), solriamfetol is neither a potent nor efficacious monoamine releaser. In rat brain synaptosomes, the highest concentration of solriamfetol tested (30 μM) resulted in submaximal DA and 5-HT release (70% and 30%, respectively) and did not promote release of NE (Fig. 2). The partial release that was observed at 30 μM solriamfetol is probably not relevant at therapeutic doses on the basis of the observation that oral daily administration of the highest therapeutic dose of solriamfetol (300 mg) in clinical studies produces a steady-state plasma C\text{max} of 8.6 μM (1670 ng/ml) in humans (Jazz Pharmaceuticals, data on file). However, further studies are necessary to elucidate the underlying mechanism(s) related to the partial DA release.
The behavioral effects of solriamfetol are similar, but not identical, to the effects of DA reuptake inhibitors and traditional stimulants. For instance, solriamfetol fully substituted for cocaine discriminative stimulus effects, with the largest dose (100 mg/kg) occasioning more than 80% cocaine-appropriate responding, probably on the basis of the overlapping mechanism of action of solriamfetol and cocaine (i.e., activity at DAT/NET). However, cocaine dose dependently increased locomotor activity, resulting in an inverted U-shaped dose-response curve, whereas the effects of solriamfetol on locomotor activity were minimal and the maximum effect was lower compared with the effects of cocaine. Finally, solriamfetol does not produce conditioned place preference or self-administration, unlike cocaine and other psychostimulants (Jazz Pharmaceuticals, data on file; Carroll and Lac, 1997; Spyraki et al., 1982; Stubler et al., 2002; Baladi et al., 2016, 2017). These differences in the behavioral effects of solriamfetol and cocaine might be the result of differences in the manner in which extracellular DA levels are increased. For instance, the increase of DA levels produced by solriamfetol is lower in magnitude and has a slower onset compared with the effects of cocaine on DA levels (Loland et al., 2012).

Results from several studies make a compelling case that the wake-promoting effects of modafinil are primarily mediated by its interaction at DAT and elevation of DA levels (for review, see Wisor (2013)). First, the wake-promoting effects of modafinil are absent in DAT-knockout mice (Wisor et al., 2001) and are attenuated by DA receptor antagonists in wild-type mice (Qu et al., 2008). Second, modafinil increases extracellular levels of DA in brain (de Saint Hilaire et al., 2001; Wisor et al., 2001; Murillo-Rodríguez et al., 2007). Third, selective DAT ligands (e.g., GBR-12909) substitute for modafinil in rats trained to discriminate modafinil from saline (Quisenberry and Baker, 2015). Although there are some studies that suggest that modafinil binds to NET in addition to DAT, the evidence is limited. For example, one study showed that modafinil displaced the binding of the radiolabeled NET ligand, \([11\text{C}] (S,S)-2-(\alpha-(2\text{-methoxyphenoxy})-benzyl)morpholine ([11\text{C}]MeNER) in living primate brain (Madras et al., 2006). One interpretation of these data, however, is that in vivo binding of [11C]MeNER is sensitive to endogenous NET substrates (Seneca et al., 2006), and there is a wealth of literature demonstrating the uptake of DA by NET (for review, see Carboni and Silvagni (2004)). Thus, it is conceivable that displacement of [11C]MeNER is not necessarily evidence of direct binding of modafinil to NET and could be a consequence of elevated extracellular DA concentrations. In addition, other studies have replicated the finding that modafinil binds to DAT but not to NET in HEK293 cells and rat brain tissue (Mignot et al., 1994; Nishino et al., 1998; Zolkowska et al., 2009; Cao et al., 2011; Loland et al., 2012). Modafinil also did not have significant functional activity at blocking the reuptake of [3H]NE in rat brain tissue (IC50 > 100,000 nM; Zolkowska et al., 2009). In contrast to modafinil, solriamfetol binds to and has activity at NET as demonstrated in the current binding, reuptake, and microdialysis studies. Further, solriamfetol dose dependently inhibited hyperactivity in DAT knockout mice, suggesting that the activity of solriamfetol is not dependent solely on interactions at DAT (Jazz Pharmaceuticals, data on file). Thus, to the extent that NE is an important neurotransmitter involved in sleep-wake regulation (Berridge and Waterhouse, 2003; Berridge, 2008;...

![Graph](image-url)
Samuels and Szabadi, 2008; Szabadi, 2013), the dual activity of solriamfetol at DAT and NET might explain differences in the therapeutic effects of solriamfetol compared with modafinil or armodafinil (Schwartz et al., 2003; Harsh et al., 2006; Ruoff et al., 2017).

The preclinical pharmacology studies presented in the current paper support the conclusion that the mechanism of action of solriamfetol involves low potency DA and NE reuptake inhibition via DAT and NET, respectively, but with distinct differences from stimulants (e.g., amphetamine) and reuptake inhibitors (e.g., cocaine and modafinil). Solriamfetol has wake-promoting effects in rodents (Hasan et al., 2009) and data from phases 2/3 studies suggest solriamfetol has therapeutic potential for the treatment of ES and impaired wakefulness in patients with narcolepsy or OSA (Ruoff et al., 2016; Strohl et al., 2017; Strollo et al., 2017; Thorpy et al., 2017). Taken together, these data suggest that solriamfetol might offer an important advance in the treatment of ES in narcolepsy and OSA as well as other clinical conditions in which ES and impaired wakefulness would benefit from pharmacological intervention.

Acknowledgments

Editorial assistance in formatting, proofreading, copy editing, and fact checking was provided by The Curry Rockefeller Group, LLC, for which ES and impaired wakefulness would benefit from pharmacological intervention.

Authorship Contributions

Participated in research design: Forster, Gatch, Mailman, Janowsky.

Conducted experiments: Gatch, Mailman, Janowsky.

Performed data analysis: Baladi, Gatch, Mailman, Hyman, Carter, Janowsky.

Wrote or contributed to the writing of the manuscript: Baladi, Forster, Gatch, Mailman, Hyman, Carter, Janowsky.

References

Aldrich MS (1989) Automobile accidents in patients with sleep disorders. Sleep 12: 487–494.

Baker LE, Riddle EE, Saunders RB, and Appel JB (1993) The role of monoamine uptake in the discriminative stimulus effects of cocaine and related compounds. Behav Pharmacol 4:39–75.

Baladi M, Black J, and Carter LP (2016) JZP-110, a dopamine norepinephrine reuptake inhibitor (DNRIL), with robust wake-promoting effects and low abuse potential. Ann Neurol 80:519.

Baladi M, Carter LP, Black J, and Bergman J (2017) Evaluation of the effects of JZP-110 in nonclinical models of abuse liability. Drug Alcohol Depend 171:E14.

Bastuji H and Jouvet M (1988) Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 12: 695–700.

Berridge CW and Waterhouse BD (2003) The locus coeruleus-noradrenergic system: Pharmacology, function, and role in disease. Annu Rev Neurosci 26:1–52.

Chapman JL, Serinel Y, Marshall NS, and Grunstein RR (2016) Residual daytime sleepiness in obstructive sleep apnea after continuous positive airway pressure optimization: causes and management. Sleep Med Clin 11:355–363.

Corne SJ, Pickering RW, and Warner BT (1963) A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br J Pharmacol Chemother 19:399–401.

Dauvilliers Y, Bassetti C, Lammers A, Arnold U, Mayer G, Rodenbeck A, Lebert P, Ding CL, Leconte JM, and Schwartz JC; HARMONY I study group (2013) Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol 12:1068–1075.

Dauvilliers Y, Neidhart E, Billiard M, and Tafti M (2002) Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil. Pharmacogenomics J 2:63–68.

Dauvilliers Y, Tafti M, and Landolt HP (2015) Catechol-O-methyltransferase, dopamine, and sleep-wake regulation. Sleep Med Rev 22:47–53.

De la Herrán-Aritx AKA and Garcia-Garcia F (2013) Current and emerging options for the treatment of narcolepsy. Sleep Med Rev 17:171–181.

Dote de Saint Hilaire Z, Oroso M, Rouche C, Blanc G, and Nicolaidis S (2001) Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport 12:3553–3557.

Eshleman AJ, Carmoli M, Cambay M, Martens CR, Neve KA, and Janowsky A (1999) Characteristics of drug interactions with recombining biogenic amine transmitters expressed in the same cell type. J Pharmacol Exp Ther 290:877–885.

Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, and Janowsky A (2013) Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85:1803–1815.

Gasa M, Tamisier R, Lavoisie SH, Sapene M, Martin F, Stach B, Grillet Y, Levy P, and Mignot E (2014) The Scientific Council of the Sleep Registry of the French Federation of Pneumology-FPF (2013) Residual sleepiness in sleep apnea patients treated by continuous positive airway pressure. J Respir Med 22:389–397.

George CF (2007) Sleep apnea, alertness, and motor vehicle crashes. Am J Respir Crit Care Med 176:954–965.

Gregory KJ, Herman ED, Ramsey AJ, Hammond AS, Byun YE, Stauffer SR, Manka JT, Jadher S, Bridges TM, Weaver CD, et al. (2015) N-arlyl piperazine membrane potential and beta receptor occupancy: evidence for a potential difference in receptor binding and efficacy in preclinical models of NM2A hypofunction and cognitive enhancement. J Pharmacol Exp Ther 347:438–457.

Halberstadt AL, Koedood L, Powell SB, and Geyer MA (2011) Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J Psychopharmacol 25:1548–1561.

Harsh JR, Hayduk R, Rosenberg R, Wessens KA, Walsh JK, Arora S, Niebler GE, and Roth T (2006) The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 22: 761–774.

Hasan S, Pradervand S, Ahnous A, Drinkenburg W, Tafti M, and Franken P (2009) How to keep the brain awake? The complex molecular pharmacogenetics of wake promotion. Neuropharmacology 44:1625–1640.

Heffner TG and Seiden LS (1988) Synthesis of cathinol cathinones from beta-lysergic acid in brain during the performance of operant behavior. Brain Res 457:403–419.

Janowsky A, Neve K, and Eshleman AJ (2001) Uptake and release of neurotransmitters. Curr Protoc Neurosci Chapter 7 Unit 7.9.

Jones BE (2000) Basic mechanisms of sleep-wake states, in Principles and Practice of Sleep Medicine, 3rd ed (Kryger MH, Roth T, and Dement WC eds) pp 134–154, Saunders, Philadelphia.

Jouvet M (1952) The role of monoamines and acetylcholine-containing neurons in the regulation of the sleep-waking cycle. Erg Physiol 64:166–307.

Kleven MS, Anthony EW, and Woolverton WL (1990) Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 254:312–317.

Krabin LE, Hershner S, Loeding LD, Maski KP, Rifkin DI, Selim B, and Watson NF (2015) Quality measures for the care of patients with narcolepsy. J Clin Sleep Med 11:1035–1041.

Lewis MM, Watts JV, Lawler CP, Nichols DE, and Mailman RB (1998) Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. J Pharmacol Exp Ther 286:356–353.

Lin JS, Sergeant EA, and Haas HL (2011) Histamine H3 receptors and sleep-wake regulation. Sleep Med Clin 6:121–128.

Loland CJ, Merue M, Okunola OM, Car J, Prinsziano TM, Mazier S, Kopatic J, Shi L, Katz JL, Tanda G, et al. (2012) R-modafinil (armodafinil): a unique dopaminergic uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry 72:405–413.

Lovenberg TW, Pyati J, Chang H, Wilson SJ, and Erlander MG (2000) Cloning of rat histamine H3 receptor reveals distinct species pharmacological profiles. J Pharmacol Exp Ther 293:771–779.

Madrid BK, Xie Z, Lin Z, Pescatola Noa Panas H, Lynch L, Johnson R, Livni E, Spencer TJ, Bonab AA, et al. (2006) Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activities in rats. J Pharmacol Exp Ther 319:561–569.

McAtee LC, Sutton SW, Rudolph DA, Li X, Abusio LE, Phuong VK, Dvorak CA, Lovenberg WW, Carruthers NI, and Jones TK (2004) Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg Med Chem Lett 14:4255–4259.

Mignot E and Nishino S (2005) Emerging therapies in narcolepsy-cataplexy. Sleep 28:754–763.

Mignot E, Nishino S, Guilleminault C, and Dement WC (1994) Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 17:436–437.

Morgenthaler TI, Kapur VK, Brown T, Swick TJ, Alessi C, Aurora RN, Bohlecke B, Chosan AL, Jr., Friedman L, Magnus R, et al.; Standards of Practice Committee of the American Academy of Sleep Medicine (2007) Practice parameters for
treatment of narcolepsy and other hypersomnias of central origin. *Sleep 30*: 1705–1711.

Mottola DM, Brewster WK, Cook LL, Nichols DE, and Mailman RB (1992) Dihy-
drexidine, a novel full efficacy D1 dopamine receptor agonist. *J Pharmacol Exp
Ther 262*: 383–393.

Mottola DM, Kibbe JD, Lewis EM, Connelly HS, Walker QD, Jones SR, Booth RG,
Hyslop DK, Pierrey M, Wightman RM, et al. (2002) Functional selectivity of do-
pamine receptor agonists. I. Selective activation of postynaptic dopamine D2 re-
ceptors linked to adenylyl cyclase. *J Pharmacol Exp Ther 300*: 1168–1178.

Murillo-Rodriguez E, Harri R, Palamos-Rivero M, Millan-Aldaco D, and Drucker-
Colin R (2007) Modafinil enhances extracellular levels of dopamine in the nucleus
accumbens and increases wakefulness in rats. *Behav Brain Res 178*: 355–357.

Nishino S, Mas J, SampaioKumar R, and Sheth J (1998) Increased dopaminergic
transmission mediates the wake-promoting effects of CNS stimulants. *Sleep
Res Online 14*: 49–61.

Ozaki A, Inoue Y, Nakajima T, Hayashida K, Honda M, Komada Y, and Takahashi K
(2008) Health-related quality of life among drug-naive patients with narcolepsy
with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without
long sleep time. *J Clin Sleep Med 4*: 572–578.

Pace-Asciak C and Watson C (1996) The Brain in Stereotactic Coordinates. 4th ed.
Academic Press, New York.

Pépin JL, Virot-Blanc V, Escourrou P, Racineux J-L, Sapone M, Lévy P, Dervaux B,
Lerone X, and Mallart A (2009) Prevalence of residual excessive sleepiness in
CPAP-treated sleep apnea patients: the French multicentre study. *Eur Respir J
33*: 1062–1067.

Qiu WM, Huang ZL, Xu XH, Matsumoto N, and Urade Y (2008) Dopaminergic D1 and
D2 receptors are essential for the arousal effect of modafinil. *J Neurosci 28*:
8462–8469.

Quinsey AJ and Baker LE (2015) Dopaminergic mediation of the discriminative
stimulus functions of modafinil in rats. *Psychopharmacology (Berl) 232*:4111–4119
Rothman RB, Mathieu BM, Dersch CM, Romero DV, Rice KC, Carroll FI,
and Partilla JS (2001) Amphetamine-type central nervous system stimulants re-
late to dopamine more potently than they release dopamine and serotonin.
*Synapse 39*: 32–41.

Ruoff C, Bogan RK, Emsellem H, Bream G, Khayrallah M, Lu Y, Carter LP, and Black J (2017) Evaluation of the effect of JZP-110 in patients with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time. *J Clin Sleep Med 4*: 572–578.

Samuels ER and Szabadi E (2008) Functional neuroanatomy of the noradrenergic
role in stimulant-induced wakefulness. *J Neurosci 33*: 28–37.

Satter G and Steier J (2012) Excessive daytime sleepiness in sleep disorders. *J
Thorac Dis 4*: 608–616.

Spearman RD (1995) Noradrenergic involvement in the discriminative stimulus ef-
effects of cocaine in squirrel monkeys. *J Pharmacol Exp Ther 275*: 53–62.

Spyraki C, Fieber HC, and Phillips AG (1982) Dopaminergic substrates of amphet-
amine-induced place preference conditioning. *Brain Res 253*: 185–193.

Stariell M and McCarley RW (1990) Brainstem Control of Wakefulness and Sleep.
Plenum, New York.

Strohl KP, Zamiel GK, Gotfried M, Chen D, Li J, Carter L, Wang H, Black J,
and Rosen CR (2017) Results of a randomized, placebo-controlled, double-blind,
12-week, multicenter study of solriamfetol (JZP-110) for the treatment of excessive
sleepiness in patients with OSA. *Chest 152*:A1062–A1063.

Strollo PJ Jr, Redline S, Hedsen J, Collip N, Lorch D, Chen D, Li J, Carter L, Lee L,
Black J, et al. (2017) Treatment of excessive sleepiness in patients with obstructive
sleep apnea: efficacy and safety results of a 6-week, double-blind, placebo-
controlled, randomized-withdrawal trial of solriamfetol (JZP-110). *Chest 152*:
A1092–A1093.

Stuber GD, Evans SB, Higgins MS, Py Y, and Figuecivic DP (2002) Food restriction
modulates amphetamine-conditioned place preference and nucleus accumbens
dopamine release in the rat. *Synapse 40*: 85–90.

Szabadi E (2013) Functional neuroanatomy of the central noradrenergic system. *J Psychopharmacol 27*:659–683.

Thorpy MJ and Daauvilleers Y (2015) Clinical and practical considerations in the
pharmacologic management of narcolepsy. *Sleep Med 16*: 9–18.

Thorpy MJ, Daauvilleers Y, Shapiro C, Mayer G, Carson BC, Chen D, Li J, Carter LP,
Wang H, Black J, et al. (2017) A randomized, placebo-controlled, phase 3 study of
the safety and efficacy of solriamfetol (JZP-110) for the treatment of excessive
sleepiness in patients with narcolepsy. *Sleep Med 40*:e327.

US Modafinil in Narcolepsy Multicenter Study Group (1998) Randomized trial of
modafinil for the treatment of pathological somnolence in narcolepsy. *Ann Neurol
43*: 88–97.

US Modafinil in Narcolepsy Multicenter Study Group (2000) Randomized trial of
modafinil as a treatment for the excessive daytime somnolence of narcolepsy.
*Neurology 54*:1166–1175.

Veasey SC, Guilleminault C, Strohl KP, Sanders MH, Ballard RD, and Magalang UJ (2006) Medical therapy for obstructive sleep apnea: a review by the Medical
Therapy for Obstructive Sleep Apnea Task Force of the Standards of Practice
Committee of the American Academy of Sleep Medicine. *Sleep 29*:1036–1044.

Walker QD and Mailman RB (1996) Triadifenol and triadifenol: effects on mono-
amine uptake and release. *J Pharmacol Exp Ther 275*:227–233.

Weaver TE and Chasnay ER (2007) Continuous positive airway pressure treatment
for sleep apnea in older adults. *Sleep Med Rev 11*:99–111.

Wisor J (2013) Modafinil as a catecholaminergic agent: empirical evidence and
unanswered questions. *Front Neurol 4*:139.

Wisor JP, Nishino S, Sera I, Uhl GH, Mignot E, and Edgar DM (2001) Dopaminergic
role in stimulant-induced wakefulness. *J Neurosci 21*:1787–1794.

Zhu Y, Fenik P, Zhang J, Mazzu E, Kelz M, Aton–Jones G, and Veasey SC (2007)
Selective loss of dopaminergic wake active neurons in a murine sleep apnea
model. *J Neurosci 27*:10060–10071.

Zolkowska D, Jain R, Rothman RD, Partilla JS, Roth BL, Setola V, Prisinzano TE,
and Baumann MH (2009) Evidence for the involvement of dopamine trans-
mission mediates the wake-promoting effects of CNS stimulants. *Sleep Res
Online 14*: 49–61.

Zolkowska D, Jain R, Rothman RD, Partilla JS, Roth BL, Setola V, Prisinzano TE,
and Baumann MH (2009) Evidence for the involvement of dopamine trans-
mission mediates the wake-promoting effects of CNS stimulants. *Sleep Res
Online 14*: 49–61.

Address correspondence to: Dr. Michelle G. Baladi, Jazz Pharmaceuticals,
3180 Porter Drive, Palo Alto, CA 94304. E-mail: Michelle.Baladi@jazzpharma.
com